Suppression of skin lesions by transdermal application of CpG-oligodeoxynucleotides in NC/Nga mice, a model of human atopic dermatitis

被引:24
作者
Inoue, Joe [1 ]
Aramaki, Yukihiko [1 ]
机构
[1] Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan
关键词
D O I
10.4049/jimmunol.178.1.584
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Atopic dermatitis (AD) is a pruritic inflammatory skin disease characterized by an elevation of the total IgE level in plasma, the infiltration of mast cells and eosinophils, and the expression of cytokines by Th2 cells. NC/Nga mice kept in conventional conditions are known to develop skin lesions resembling human AD. We examined in this study the alterations of immune response in NC/Nga mice kept in conventional conditions, following transdermal application of CpG-oligodeoxynucleotides (ODN), which plays a critical role in immunity via the augmentation of Th1-type and suppression of Th2-type responses. CpG-ODN remarkably changed the immune response from type Th2 to Th1 as determined from cytokine mRNA and Ab levels. The serum IgE level was decreased and the expression of IgG2a was up-regulated. The application of CpG-ODN to the skin also decreased inflammatory infiltration of mast cells, and suppression in the skin lesions was observed. Furthermore, the generation of regulatory T cells, which are considered immune suppressive T cells, was observed in the skin on treatment with CpG-ODN. These results suggested CpG-ODN is effective for immunotherapy in patients with AD, which is characterized by Th2-dominated inflammation.
引用
收藏
页码:584 / 591
页数:8
相关论文
共 39 条
[11]   Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice [J].
Inoue, J ;
Yotsumoto, S ;
Sakamoto, T ;
Tsuchiya, S ;
Aramaki, Y .
JOURNAL OF CONTROLLED RELEASE, 2005, 108 (2-3) :294-305
[12]   Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice [J].
Inoue, J ;
Yotsumoto, S ;
Sakamoto, T ;
Tsuchiya, S ;
Aramaki, Y .
PHARMACEUTICAL RESEARCH, 2005, 22 (10) :1627-1633
[13]   Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses [J].
Kitagaki, K ;
Jain, VV ;
Businga, TR ;
Hussain, I ;
Kline, JN .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002, 9 (06) :1260-1269
[14]   Treatment of established asthma in a murine model using CpG oligodeoxynucleotides [J].
Kline, JN ;
Kitagaki, K ;
Businga, TR ;
Jain, VV .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2002, 283 (01) :L170-L179
[15]  
Kline JN, 1998, J IMMUNOL, V160, P2555
[16]   Use of CpG oligodeoxynucleotides as immune adjuvants [J].
Klinman, DM ;
Currie, D ;
Gursel, I ;
Verthelyi, D .
IMMUNOLOGICAL REVIEWS, 2004, 199 (01) :201-216
[17]  
KONDO K., 1969, Comparative cellular and species radiosensitivity., P20
[18]   Development of a novel Ag-specific immunotherapy using CpG oligodeoxynucleotides in a new, unique mouse cutaneous eosinophilic inflammation model [J].
Kootiratrakarn, T ;
Fujimura, T ;
Sano, K ;
Okuyama, R ;
Aiba, S ;
Tagami, H ;
Terui, T .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (11) :3277-3286
[19]   CpG motifs in bacterial DNA and their immune effects [J].
Krieg, AM .
ANNUAL REVIEW OF IMMUNOLOGY, 2002, 20 :709-760
[20]   New insights into atopic dermatitis [J].
Leung, DYM ;
Boguniewicz, M ;
Howell, MD ;
Nomura, I ;
Hamid, OA .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (05) :651-657